 |
|
|
|
|
 |
Last Updated: Sep 8, 2007 - 1:21:03 PM |
Latest Research
:
Pharmacology
:
Metals
:
Lanthanum
Higher Initial Doses of FOSRENOL Result in More Rapid Control of Mean Serum Phosphorus
According to data presented today at the National Kidney Foundation's (NKF) 2006 clinical meeting in Chicago, IL, a conversion to the non-calcium phosphate binder FOSRENOL (lanthanum carbonate) from other phosphate binder therapies provides continued mean serum phosphorus control for end-stage renal disease (ESRD) patients with hyperphosphatemia, while significantly reducing their daily tablet burden and the total daily dose of phosphate binder medication.
Apr 23, 2006 - 7:11:00 PM
|
<< prev
next >>
|
|
|
|
